Saudi Arabia builds the AI factories of the future with NVIDIA

Saudi Arabia builds the AI factories of the future with NVIDIA

The Saudi AI company HUMAIN, supported by the state Public Investment Fund, has entered into a strategic partnership with NVIDIA. Together, they plan to build AI factories with a capacity of up to 500 megawatts, equipped with hundreds of thousands of NVIDIA's most powerful GPUs. In the first phase, a supercomputer with 18,000 GB300 Grace Blackwell chips will be installed to enable the development and deployment of advanced AI models.

This initiative is a key part of Saudi Arabia's Vision 2030, which aims to diversify the economy and make the country a global center for artificial intelligence. Through the use of NVIDIA's Omniverse platform, digital twins will be created to simulate and optimize physical processes in areas such as energy, logistics and manufacturing.

For the AI community, this is a significant step towards a world where AI is embedded not only in software but also in physical infrastructure. It demonstrates how strategic partnerships and investments can drive the development and implementation of AI technologies on a global scale.

Why it matters: This partnership marks a significant milestone in global AI development by demonstrating how countries can strengthen their position in the digital future through strategic investments and collaborations. For the AI community, this opens up new opportunities for innovation, collaboration and the practical application of AI technologies at scale.

Get Your Free ChatGPT Productivity Bundle

Mindstream brings you 5 essential resources to master ChatGPT at work. This free bundle includes decision flowcharts, prompt templates, and our 2025 guide to AI productivity.

Our team of AI experts has packaged the most actionable ChatGPT hacks that are actually working for top marketers and founders. Save hours each week with these proven workflows.

It's completely free when you subscribe to our daily AI newsletter.

Subscribe to get instant access

What to Expect at Google I/O 2024: AI, Android 16, and Gemini Upgrades

Google I/O 2024 kicks off May 20–21, and all eyes are on major AI reveals, especially upgrades to its Gemini models and the possible launch of new premium tiers. The event will also spotlight Project Astra and Mariner—AI agents designed for real-time interaction and autonomous web navigation. Android 16 will debut with quality-of-life upgrades like Material 3 Expressive design, Auracast support, and new lock screen widgets. Expect surprises too, including potential updates to NotebookLM and Google’s video-generating model, Veo 2.

Reasoning scaling will likely slow down by 2026. Do we need another breakthrough?

Telomere-lengthening gene therapy EXG-34217

An initial clinical trial successfully lengthened the telomeres of bone marrow stem cells in patients with telomere biology disorders. The gene therapy introduces the reprogramming gene ZSCAN4 and normalized neutrophil counts and telomere length without side effects. This brings targeted rejuvenation of depleted cell reservoirs within reach—a foundation for regenerative therapies that could also delay the general aging process in the future.

Senolytics improve cognition

The STAMINA pilot study showed that a two-day, biweekly regimen of dasatinib + quercetin reduces senescent cells, increases cognitive scores by an average of two points in older people at risk of Alzheimer's disease, and lowers inflammation markers. Despite the small number of participants, the results underscore the potential of senolytics to slow brain aging pharmacologically—an important step toward a healthier, longer life span.

NewLimit raises $130 million

The longevity startup launched by Coinbase founder Brian Armstrong receives Series B funding from Kleiner Perkins & Co. to develop epigenetic reprogramming therapies. The goal is to reset age-related gene expression patterns rather than treat symptoms. The capital will accelerate preclinical programs and bring regulatory studies within reach – a sign that investors are now serious about scaling up the “age as a disease” strategy.